Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CCR5 | P51681 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | XBP1 | P17861 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.38 |
| ▸ | CDK9 | P50750 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 4/20 | 0.38 |
| ▸ | JAK1 | P23458 | 4/20 | 0.38 |
| ▸ | ACHE | P22303 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4116966 | 0.99 | CHRM2 (0.40) | CHRM2CHRM3CYP3A4CCR5DRD2 | |
| SCHEMBL13800844 | 0.96 | CHRM2 (0.38) | CHRM2CHRM3CYP3A4CCR5DRD2 | |
| SCHEMBL13800827 | 0.96 | HCRTR1 (0.45) | CHRM2CHRM3CYP3A4CCR5DRD2 | |
| SCHEMBL13800842 | 0.96 | CHRM2 (0.38) | CHRM2CHRM3CYP3A4CCR5DRD2 | |
| SCHEMBL13800825 | 0.96 | HCRTR1 (0.45) | CHRM2CHRM3CYP3A4CCR5DRD2 | |
| Hydrochloric Acid SCHEMBL6184742 | 0.95 | CHRM2 (0.38) | CHRM2CHRM3CYP3A4CCR5DRD2 | |
| SCHEMBL13800834 | 0.95 | WNK1 (0.43) | CHRM2CHRM3CYP3A4DRD2DRD4 | |
| SCHEMBL13800882 | 0.95 | CCNT1 (0.40) | CHRM2CHRM3CYP3A4CCR5DRD2 | |
| SCHEMBL6166365 | 0.95 | DRD4 (0.45) | CHRM2CHRM3CYP3A4DRD2DRD4 | |
| Hydrochloric Acid SCHEMBL7225266 | 0.95 | CHRM2 (0.38) | CHRM2CHRM3CYP3A4CCR5DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043078-A1 | Angiogenesis inhibitor | KOWA CO., LTD. (JP) | 2007-02-22 | — | — | US | claimed |
| EP-1674100-A1 | ANGIOGENESIS INHIBITOR | Kowa Co., Ltd. (JP) | 2006-06-28 | — | — | EP | claimed |
| US-20050176764-A1 | Medicine for treating cancer | KOWA CO., LTD (JP) | 2005-08-11 | — | — | US | claimed |
| EP-1494670-A1 | MEDICINE FOR TREATING CANCER | Kowa Co., Ltd. (JP) | 2005-01-12 | — | — | EP | claimed |
| WO-2003086397-A1 | MEDICINE FOR TREATING CANCER | KOWA CO., LTD. (JP) | 2003-10-23 | — | — | WO | claimed |
| US-20090143430-A1 | ERYTHROPOIETIN PRODUCTION ACCELERATOR | KOWA CO., LTD. (JP) | 2009-06-04 | — | — | US | disclosed |
| US-20090143430-A1 | ERYTHROPOIETIN PRODUCTION ACCELERATOR | KOWA CO., LTD. (JP) | 2009-06-04 | — | — | US | disclosed |
| US-20090042901-A1 | AGENT FOR PREVENTION/THERAPY OF DISEASE CAUSED BY KERATINOCYTE GROWTH | KOWA CO., LTD. (JP) | 2009-02-12 | — | — | US | disclosed |
| US-20090042901-A1 | AGENT FOR PREVENTION/THERAPY OF DISEASE CAUSED BY KERATINOCYTE GROWTH | KOWA CO., LTD. (JP) | 2009-02-12 | — | — | US | disclosed |
| US-20070043078-A1 | Angiogenesis inhibitor | KOWA CO., LTD. (JP) | 2007-02-22 | — | — | US | disclosed |
| EP-1674100-A1 | ANGIOGENESIS INHIBITOR | Kowa Co., Ltd. (JP) | 2006-06-28 | — | — | EP | disclosed |
| US-20050025979-A1 | Multilayer; containing hot melt adhesives ; heat sealable laminate with ink or graphic layer on flexible substrate | SANDT RICHARD L (US) | 2005-02-03 | — | — | US | disclosed |
| US-4722835-A | STABLE; PROCESSED AT LOWER TEMPERATURES | AMERICAN CYANAMID COMPANY (US) | 1988-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176764-A1 | Medicine for treating cancer | HDAC4, HDAC3, NR4A3 | CHRM2 1300/4885CHRM3 1030/4885CYP3A4 1615/4885 |
| US-20070043078-A1 | Angiogenesis inhibitor | FLT4, FLT1, KDR | CHRM2 2042/4885CHRM3 2319/4885CYP3A4 1362/4885 |
| US-20090143430-A1 | ERYTHROPOIETIN PRODUCTION ACCELERATOR | EPOR, GHRHR, ARL1 | CHRM2 2158/4885CHRM3 2302/4885CYP3A4 3032/4885 |
| US-20090042901-A1 | AGENT FOR PREVENTION/THERAPY OF DISEASE CAUSED BY KERATINOCYTE GROWTH | KRT18, FGF1, AREG | CHRM2 3470/4885CHRM3 3474/4885CYP3A4 4858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.